Oncotarget: Fighting Cancer with Efficiency

// Published February 14, 2017 by User1

Oncotarget is a weekly peer-reviewed open access medical journal that was established in 2010. The journal has published research papers involving cancer research and oncology. However, they have recently began publishing papers in the fields of endocrinology, pathology, age-related diseases and immunology. The journal has had great success since 2011 and is considered to be the best in its field. Their success can be attributed to their publishing methods and the commitment of their editors to produce quality content.

Oncotarget releases their issues weekly and all issues can be printed on demand. Their mission is to expedite the availability of research results. They use the latest digital technology to achieve this mission. They also maximize the impact of research results through a rigid peer review process. Oncotarget has published several groundbreaking articles which have made a positive impact in the medical community. Arguably, the most well known is the impactful study on E-Cigarettes.

Andrei Gudkov and Mikhail Blagoskionny are the Editors-In-Chief of Oncotarget that is being published by Impact Journals. They both are professors at the Roswell Park Cancer Institute. Dr. Gudkov is a pre-eminent cancer researcher and Dr. Blagoskionny is a professor of oncology. Both Gudkov and Blagoskionny are committed to publishing research that foster clinical and basic science applications to fight disease. The success of Oncotarget can be attributed to the strict editorial standards of these two pre-eminent scientists.

In summary, the key to Oncotarget’s success is simple. They use passion along with an individual approach. They have managed to combine thorough peer-review with rapid publication. The passion of their editors have been essential. It is said that submissions can be reviewed by 3 reviewer within one hour of submission. Oncotarget accomplishes their mission through passion and efficiency. It is also available in dovepress.com.

Leave a Reply

Your email address will not be published. Required fields are marked *